Home New England New Haven, CT Cybrexa, Inc. COMPANY
Clinical Phase 2
Cybrexa's alphalex is a tumor-targeting platform used to create new applications and combinations of existing cancer therapeutics. From company website Source · Oct 12, 2026
Keywords: oncology cancer Epithelial Ovarian Cancer Small Cell Lung Carcinoma Breast Cancer Colorectal Cancer Pancreas Cancer Appendix Cancer Non-small Cell Lung Cancer Gastric Cancer Esophagus Cancer Urothelial Carcinoma Sarcoma Platinum-resistant Ovarian Cancer Refractory Ovarian Carcinoma CBX-12 Show all 16 keywords
Profile checked Oct 10, 2026
At a glance Region New England Stage Clinical Phase 2 Latest trial Phase 2: A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer (Sep 25, 2024) source Timeline Sep 25, 2024 Trial start Phase 2: A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer source ↗ May 3, 2021 Trial start Phase 1/Phase 2: Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors source ↗ Clinical trials (lead sponsor) 2 Record Title Phase Status Start Primary completion NCT04902872 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors Phase 1/Phase 2 Completed May 3, 2021 Jun 24, 2025 (actual) NCT06315491 A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer Phase 2 Terminated Sep 25, 2024 Oct 31, 2025 (actual)
